DDInter1638 DDInter1657
Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain.
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Samarium (153Sm) lexidronam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Foscarnet
Samarium (153Sm) lexidronam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Altretamine
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Polatuzumab vedotin
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Altretamine
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Polatuzumab vedotin